ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. It combines an atypical antipsychotic efficacy profile with... It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.
- Mechanism
- Curator reviewed
ACP-104 combines M1 muscarinic agonism, 5-HT2A inverse agonism, and D2 and D3 dopamine partial agonism in a single compound. ACP-104 uniquely stimulates brain cells known as M1 muscarinic receptors that play an important role in cognition. ACP-104 is a partial-agonist that causes weak activation of dopamine D2 and D3 receptors. These partial agonist properties of ACP-104 may lead to less motoric side effects than seen with most other antipsychotic drugs.
- Primary indication
- Investigated for use/treatment in schizophrenia and schizoaffective disorders.Curator reviewed
- Formula / weight
- C17H17ClN4 · 312.797 g/mol (avg)
- Also known as
- Demethylclozapine · Desmethylclozapine · N-Desmethylclozapine
- Code names
- ACP-104
Resolves to
JNNOSTQEZICQQP-UHFFFAOYSA-NSMILESClC1=CC=C2NC3=C(C=CC=C3)C(=NC2=C1)N1CCNCC1What you can answer from here — as of January 29, 2025
Which drugs share a target with Norclozapine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account